Table 1.
Antidiabetic drugs in clinical trials for neurodegenerative diseases
| Drug | Type | Status | Data availability statement |
|---|---|---|---|
| Liraglutide | GLP‐1 analog | FDA approved drug for T2DM and in phase IIb clinical trial (NCT01843075) (Batista et al., 2018; Femminella et al., 2019) for AD | The data that support the findings of this study are openly available in PubMed at https://doi.org/10.1002/path.5056 (Batista et al., 2018) |
| Pioglitazone | Peroxisome proliferator‐activated receptor gamma (PPAR‐gamma) agonist, thiazolidinedione insulin sensitizer | FDA approved drug for T2DM and in phase II clinical trial for AD (NCT00982202) (Galimberti & Scarpini, 2017; Geldmacher, Fritsch, McClendon, & Landreth, 2011) | The data that support the findings of this study are openly available in PubMed at https://doi:10.1001/archneurol.2010.229 (Geldmacher et al., 2011) |
| Exendin‐4 (or Exenatide) | GLP‐1 agonist | FDA approved for T2DM and in phase II clinical trial for AD and (NCT02847403) Parkinson's disease (NCT01174810) (Aviles‐Olmos et al., 2013) | The data that support the findings of this study are openly available in PubMed at https://doi.org/10.1172/JCI68295 (Aviles‐Olmos et al., 2013) |
| Lixisenatide/Adlyxin | GLP‐1 receptor agonist | FDA approved drug for T2DM and in phase II clinical trial for PD (NCT03439943) | The data that support the findings of this study are openly available in Clinical Trials at https://clinicaltrials.gov/ct2/show/NCT03439943 (Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease n.d.) |
| Metformin | Biguanide‐Insulin sensitizer | FDA approved drug for T2DM and in phase II clinical trial for AD (NCT00620191) | The data that support the findings of this study are openly available in PubMed at https://10.1212/01.wnl.0000140292.04932.87 (Luchsinger, Tang, Shea, & Mayeux, 2004) |
| Telmisartan | Telmisartan is an Angiotensin 2 receptor blocker | FDA approved drug for hypertension and in phase III clinical trial (NCT00274118) for T2DM and in phase III clinical trial for AD (NCT00274118) (Cummings, Lee, Ritter, & Zhong, 2018) | The data that support the findings of this study are openly available in PubMed at https://doi.org/10.1016/j.trci.2018.03.009 (Cummings et al., 2018) |
Sources: clinicaltrials.gov and druginfo.nlm.nih.gov